Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone
synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2
and 5 anti-hypertensive (AHT) medications.